Results 201 to 210 of about 209,106 (262)

Case Report: Triple-negative metaplastic breast carcinoma with primary resistance to neoadjuvant chemoimmunotherapy, refractory tumor necrosis-related fever, and rapid postoperative disease progression. [PDF]

Front Oncol
Hu L, Luo Y, Luo J.
europepmc   +1 more source

Pretreatment EBV‐DNA/TLG‐Based Risk Stratification Is Associated With Survival Outcomes in Nonmetastatic Nasopharyngeal Carcinoma: An Exploratory Study

International Journal of Cancer, EarlyView.
ABSTRACT Whether combining pretreatment plasma Epstein–Barr virus DNA (EBV‐DNA) with 18F‐FDG PET/CT‐derived total lesion glycolysis (TLG) improves prognostic stratification in nonmetastatic nasopharyngeal carcinoma (NPC) is unclear, particularly in nonendemic populations.
Mehmet Çağrı Duymaz, Ece Özkaya Duymaz, Nazlı Ünsal, Recep Bekiş, Büşra Tozduman, Özgür Appak, Ayşe Demiral, Oğuz Çetinayak   +7 more
wiley   +1 more source

Impact of Residual Mediastinal Nodal Disease After Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer. [PDF]

Cancers (Basel)
Mosleh B, Papaporfyriou A, Fuereder T, Prosch H, Widder J, Oberndorfer F, Aigner C, Idzko M, Gompelmann D, Hoda MA.   +9 more
europepmc   +1 more source

Incidence and Predictors of Immune‐Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real‐World Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) frequently cause thyroid immune‐related adverse events (irAEs). Permanent hypothyroidism, the clinically most relevant phenotype, requires lifelong hormone replacement. We investigated its incidence, course, risk factors, and prognostic relevance under pembrolizumab.
Freya Koffka, Johann Kornowski, Elena Laakmann, Barbara Schmalfeldt, Tim Zell, Glenn Geidel, Christoffer Gebhardt, Pia Roser, Volkmar Müller, Julian Kött   +9 more
wiley   +1 more source

Comparative outcomes of neoadjuvant immunochemotherapy versus neoadjuvant chemoradiotherapy in locally advanced thoracic esophageal squamous cell carcinoma: a target trial emulation. [PDF]

Front Immunol
Li Z, Zhou Q, Xie Q, Wang C, Peng L, Han Y, Leng X, Miao Y, Zhang Q, He W.   +9 more
europepmc   +1 more source

Improved Prediction of Colon Cancer Recurrence Using the ColoNode mRNA Test: A 5‐Year Survival Analysis

International Journal of Cancer, EarlyView.
ABSTRACT Twenty‐five percent of colon cancer patients having curative surgery will recur. Most of them will die from distant metastasis partly due to shortcomings of routine histopathological analysis, that is, undetected tumor cells in the regional lymph node field.
Basel Sitohy, Gudrun Lindmark, Anne Israelsson, Lina Olsson, Tamer Roshdy, Joel Blomqvist, Sara Kero, Mattias Söderholm, Annamaria Turi, Thorbjörn Sakari, Michiel Dooper, George Dafnis, Pehr Forsberg, Susanne Skovsted, Maria Walldén, Chih‐Han Kung, Martin Rutegård, Johanna Nordmyr, Måns Muhrbeck, Sten Hammarström, Marie‐Louise Hammarström   +20 more
wiley   +1 more source

Efficacy and safety of neoadjuvant treatment with PD-1 inhibitor in locally advanced head and neck squamous cell carcinoma. [PDF]

Front Oncol
Xu S, Zheng H, Liao X, Jiang M, Peng H, Liu M.   +5 more
europepmc   +1 more source

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long‐Term Survival Outcomes

International Journal of Cancer, EarlyView.
ABSTRACT Long‐term survival data for patients with locally advanced gastro‐esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long‐term disease‐free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with ...
Thierry Alcindor, James Tankel, Pierre‐Olivier Fiset, Mehrnoush Dehghani, Nicholas Bertos, Carmen Mueller, Jonathan Cools‐Lartigue, Sophie Camilleri‐Broet, Lorenzo Ferri   +8 more
wiley   +1 more source